bioAffinity Technologies, Inc. (BIAF) Form S-3 — Aug 27, 2026
bioAffinity Technologies filed an S-3 registering up to 1,709,334 shares of common stock for resale by selling stockholders, chiefly warrant shares from an August 2026 private placement with Armistice Capital Master Fund. The company receives no proceeds from these resales, though a full cash exercise of the underlying warrants would deliver roughly $8.2 million. The shares stem from an August 12, 2026 purchase agreement priced at $6.9855 per pre-funded warrant, which closed August 14 and netted bioAffinity approximately $3.6 million for working capital and general corporate purposes. WallachBeth Capital acted as placement agent, earning a 7.5% cash fee plus warrants on 16,926 shares.
Key figures
- Gross Proceeds
- approximately $8.2 million contingent on cash exercise of all registered warrants; company receives no proceeds from resale sales
- Shares Offered
- 1709334
- Shares Outstanding
- 592,327 prior to offering; 2,301,661 after full warrant exercise
- Warrant term years
- 5
- Placement agent fee
- 7.5% of gross proceeds
- Reverse split ratio
- 1:15
- Last sale price date
- August 26, 2026
- Placement net proceeds
- approximately $3.6 million
- Last reported sale price
- 5.09
- Armistice shares registered
- 1692408
- Estimated registration expenses
- 86612
- Prefunded warrant exercise price
- 0.105
- Prefunded warrant purchase price
- 6.9855
- Series a b warrant exercise price
- 7.0905
Price after filing
Close on the filing date to close N calendar days later (from $5.06). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.